Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Proximal spinal muscular atrophy (SMA) is a common neuromuscular disorder causing infant death in half of all patients. Homozygous absence of the survival motor neuron gene (SMN1) is the primary cause of SMA, while SMA severity is mainly determined by the number of SMN2 copies. One SMN2 copy produces only about 10% of full-length protein identical to SMN1, whereas the majority of SMN2 transcripts is aberrantly spliced due to a silent mutation within an exonic splicing enhancer in exon 7. However, correct splicing can be restored by over-expression of the SR-like splicing factor Htra2-beta 1. We show that in fibroblast cultures derived from SMA patients treated with therapeutic doses (0.5-500 microM) of valproic acid (VPA), the level of full-length SMN2 mRNA/protein increased 2- to 4-fold. Importantly, this up-regulation of SMN could be most likely attributed to increased levels of Htra2-beta 1 which facilitates the correct splicing of SMN2 RNA as well as to an SMN gene transcription activation. Especially at low VPA concentrations, the restored SMN level depended on the number of SMN2 copies. Moreover, VPA was able to increase SMN protein levels through transcription activation in organotypic hippocampal brain slices from rats. Finally, VPA also increased the expression of further SR proteins, which may have important implications for other disorders affected by alternative splicing. Since VPA is a drug highly successfully used in long-term epilepsy therapy, our findings open the exciting perspective for a first causal therapy of an inherited disease by elevating the SMN2 transcription level and restoring its correct splicing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
A simple method for organotypic cultures of nervous tissue
Stoppini, L., Buchs, P.-A., & Muller, D. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90128-m · Cited by 3,089
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Cartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Wirth, B. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200003)15:3<228::aid-humu3>3.0.co;2-9 · Cited by 667
International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)
Munsat, T. L., & Davies, K. E. (1992) · Neuromuscular Disorders · doi:10.1016/s0960-8966(06)80015-5 · Cited by 666
Cited by
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Lunn, M. R., & Wang, C. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60921-6 · Cited by 995
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
Kolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 603
Le, T. T., Pham, L. T., Butchbach, M. E. R., Zhang, H. L., Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J., & Burghes, A. H. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi078 · Cited by 598
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function
Swoboda, K. J., Prior, T. W., Scott, C. B., McNaught, T. P., Wride, M. C., Reyna, S. P., & Bromberg, M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20473 · Cited by 478
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients
O’Hagen, J. M., Glanzman, A. M., McDermott, M. P., Ryan, P. A., Flickinger, J., Quigley, J., Riley, S., Sanborn, E., Irvine, C., Martens, W. B., et al. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.05.009 · Cited by 380
Wirth, B., Brichta, L., Schrank, B., Lochmüller, H., Blick, S., Baasner, A., & Heller, R. (2006) · Human Genetics · doi:10.1007/s00439-006-0156-7 · Cited by 355
Self-citationSpinal Muscular Atrophy: A Deficiency in a Ubiquitous Protein; a Motor Neuron-Specific Disease
Monani, U. R. (2005) · Neuron · doi:10.1016/j.neuron.2005.12.001 · Cited by 350
Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy
Avila, A. M., Burnett, B. G., Taye, A. A., Gabanella, F., Knight, M. A., Hartenstein, P., Cizman, Z., Di Prospero, N. A., Pellizzoni, L., Fischbeck, K. H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29562 · Cited by 350
Shukla, S., & Tekwani, B. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00537 · Cited by 314
Passini, M. A., Bu, J., Roskelley, E. M., Richards, A. M., Sardi, S. P., O’Riordan, C. R., Klinger, K. W., Shihabuddin, L. S., & Cheng, S. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41615 · Cited by 292
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
Wirth, B., Karakaya, M., Kye, M. J., & Mendoza-Ferreira, N. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-102319-103602 · Cited by 255
Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Monti, B., Polazzi, E., & Contestabile, A. (2009) · Current Molecular Pharmacology · doi:10.2174/1874-470210902010095 · Cited by 239
SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy
Riessland, M., Ackermann, B., Förster, A., Jakubik, M., Hauke, J., Garbes, L., Fritzsche, I., Mende, Y., Blumcke, I., Hahnen, E., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq023 · Cited by 220
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders
Butler, R., & Bates, G. P. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1989 · Cited by 214
Darras, B. T. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.03.010 · Cited by 201
Pujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201
Spinal Muscular Atrophy: A Clinical and Research Update
Markowitz, J. A., Singh, P., & Darras, B. T. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2011.09.001 · Cited by 188
Bora-Tatar, G., Dayangaç-Erden, D., Demir, A. S., Dalkara, S., Yelekçi, K., & Erdem-Yurter, H. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.042 · Cited by 178
Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy
Swoboda, K. J., Scott, C. B., Reyna, S. P., Prior, T. W., LaSalle, B., Sorenson, S. L., Wood, J., Acsadi, G., Crawford, T. O., Kissel, J. T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005268 · Cited by 176
Swoboda, K. J., Scott, C. B., Crawford, T. O., Simard, L. R., Reyna, S. P., Krosschell, K. J., Acsadi, G., Elsheik, B., Schroth, M. K., D'Anjou, G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012140 · Cited by 174
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy
Mercuri, E., Bertini, E., Messina, S., Solari, A., D'Amico, A., Angelozzi, C., Battini, R., Berardinelli, A., Boffi, P., Bruno, C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000249142.82285.d6 · Cited by 172
Zheng, Z.-M. (2004) · Journal of Biomedical Science · doi:10.1007/bf02254432 · Cited by 172
Chaytow, H., Faller, K. M. E., Huang, Y.-T., & Gillingwater, T. H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100346 · Cited by 165
Histone deacetylase inhibitors: possible implications for neurodegenerative disorders
Hahnen, E., Hauke, J., Tränkle, C., Eyüpoglu, I. Y., Wirth, B., & Blümcke, I. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.169 · Cited by 165
The role of histone acetylation in SMN gene expression
Kernochan, L. E., Russo, M. L., Woodling, N. S., Huynh, T. N., Avila, A. M., Fischbeck, K. H., & Sumner, C. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi130 · Cited by 164
Lunn, M. R., Root, D. E., Martino, A. M., Flaherty, S. P., Kelley, B. P., Coovert, D. D., Burghes, A. H., thi Man, N., Morris, G. E., Zhou, J., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.08.024 · Cited by 160
Constructing and Deconstructing Stem Cell Models of Neurological Disease
Han, S. S. W., Williams, L. A., & Eggan, K. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.003 · Cited by 159
Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
Nishio, H., Niba, E. T. E., Saito, T., Okamoto, K., Takeshima, Y., & Awano, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511939 · Cited by 201
Rescue of a human mRNA splicing defect by the plant cytokinin kinetin
Slaugenhaupt, S. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddh046 · Cited by 153
Jarecki, J., Chen, X., Bernardino, A., Coovert, D. D., Whitney, M., Burghes, A. H. M., Stack, J. H., & Pollok, B. A. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi205 · Cited by 158
Hahnen, E., Eyüpoglu, I. Y., Brichta, L., Haastert‐Talini, K., Tränkle, C., Siebzehnrübl, F. A., Rießland, M., Hölker, I., Claus, P., Romstöck, J., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03868.x · Cited by 157
Self-citationThe spinal muscular atrophy disease protein SMN is linked to the rho-kinase pathway via profilin
Nölle, A., Zeug, A., van Bergeijk, J., Tönges, L., Gerhard, R., Brinkmann, H., Rayes, S. A., Hensel, N., Schill, Y., Aphkhazava, D., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr425 · Cited by 146
Spinal muscular atrophy: molecular genetics and diagnostics
Ogino, S., & Wilson, R. B. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.1.15 · Cited by 144
A natural history study of late onset spinal muscular atrophy types 3b and 4
Piepers, S., van den Berg, L. H., Brugman, F., Scheffer, H., Ruiterkamp‐Versteeg, M., van Engelen, B. G. M., Faber, C. G., de Visser, M., van der Pol, W. L., & Wokke, J. H. J. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0929-0 · Cited by 140
Hauke, J., Rießland, M., Lunke, S., Eyüpoglu, I. Y., Blümcke, I., El‐Osta, A., Wirth, B., & Hahnen, E. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn357 · Cited by 155
In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate
Brichta, L., Hölker, I., Haug, K., Klockgether, T., & Wirth, B. (2006) · Annals of Neurology · doi:10.1002/ana.20836 · Cited by 138
Self-citationWolstencroft, E. C. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi131 · Cited by 135
DcpS as a Therapeutic Target for Spinal Muscular Atrophy
Singh, J., Salcius, M., Liu, S.-W., Staker, B. L., Mishra, R. K., Thurmond, J., Michaud, G. A., Mattoon, D., Printen, J. A., Christensen, J., et al. (2008) · ACS Chemical Biology · doi:10.1021/cb800120t · Cited by 133
Spinal Muscular Atrophy: From Gene to Therapy
Wirth, B., Brichta, L., & Hahnen, E. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.06.008 · Cited by 142
Self-citationAckermann, B., Kröber, S., Torres‐Benito, L., Borgmann, A., Peters, M., Hosseinibarkooie, S., Tejero, R., Jakubik, M., Schreml, J., Milbradt, J., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds540 · Cited by 158
Rießland, M., Brichta, L., Hahnen, E., & Wirth, B. (2006) · Human Genetics · doi:10.1007/s00439-006-0186-1 · Cited by 126
Self-citationSoret, J., Bakkour, N., Maire, S., Durand, S., Zekri, L., Gabut, M., Fic, W., Divita, G., Rivalle, C., Dauzonne, D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409829102 · Cited by 124
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis
Piepers, S., Veldink, J. H., de Jong, S. W., van der Tweel, I., van der Pol, W. L., Uijtendaal, E. V., Schelhaas, H. J., Scheffer, H., de Visser, M., de Jong, J. M. B. V., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21620 · Cited by 137
Heier, C. R., & DiDonato, C. J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp030 · Cited by 123
Kissel, J. T., Scott, C., Reyna, S. P., Crawford, T. O., Simard, L. R., Krosschell, K. J., Acsádi, G., Elsheik, B., Schroth, M. K., D’Anjou, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021296 · Cited by 138
The promise and perils of HDAC inhibitors in neurodegeneration
Didonna, A., & Opal, P. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.147 · Cited by 134
Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy
Weihl, C. C., Connolly, A. M., & Pestronk, A. (2006) · Neurology · doi:10.1212/01.wnl.0000231139.26253.d0 · Cited by 121
Butchbach, M. E. R., Singh, J., Þorsteinsdóttir, M., Saieva, L., Slominski, E., Thurmond, J., Andrésson, Þ., Zhang, J., Edwards, J. D., Simard, L. R., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp510 · Cited by 119
The methylation hypothesis: Do epigenetic chromatin modifications play a role in epileptogenesis?
Kobow, K., & Blümcke, I. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03145.x · Cited by 126
Baughan, T. D., Dickson, A. L., Osman, E. Y., & Lorson, C. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp076 · Cited by 124
Eyüpoglu, I. Y., Hahnen, E., Buslei, R., Siebzehnrübl, F. A., Savaskan, N. E., Lüders, M., Tränkle, C., Wick, W., Weller, M., Fahlbusch, R., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03098.x · Cited by 130
Oral valproic acid for epilepsy - long-term experience in therapy and side effects
Gerstner, T. A., Bell, N. V. T., & König, S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.285 · Cited by 115
Cuscó, I., Barceló, M. J., Rojas‐García, R., Illa, I., Gámez, J., Cervera, C., Serradell, A. P., Izquierdo, G., Baiget, M., & Tizzano, E. F. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0912-y · Cited by 114
Spinal muscular atrophy: the RNP connection
Eggert, C., Chari, A., Laggerbauer, B., & Fischer, U. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.01.005 · Cited by 120
Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice
Tsai, L., Tsai, M., Ting, C.-H., & Li, H. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0388-1 · Cited by 117
Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells
Grzeschik, S. M., Ganta, M., Prior, T. W., Heavlin, W. D., & Wang, C. H. (2005) · Annals of Neurology · doi:10.1002/ana.20548 · Cited by 113
Garbes, L., Rießland, M., Hölker, I., Heller, R., Hauke, J., Tränkle, C., Coras, R., Blümcke, I., Hahnen, E., & Wirth, B. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp313 · Cited by 110
Jansen, M. S., Nagel, S. C., Miranda, P. J., Lobenhofer, E. K., Afshari, C. A., & McDonnell, D. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402014101 · Cited by 120
Yoshida, M., Kitaoka, S., Egawa, N., Yamane, M., Ikeda, R., Tsukita, K., Amano, N., Watanabe, A., Morimoto, M., Takahashi, J., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.010 · Cited by 102
Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts
Mattis, V. B., Rai, R. P., Wang, J., Chang, C. T., Coady, T. H., & Lorson, C. L. (2006) · Human Genetics · doi:10.1007/s00439-006-0245-7 · Cited by 102
El‐Khodor, B. F., Edgar, N. M., Chen, A., Winberg, M. L., Joyce, C. L., Brunner, D., Suárez‐Fariñas, M., & Heyes, M. P. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.02.025 · Cited by 101
Drug treatment for spinal muscular atrophy types II and III
Wadman, R. I., Bosboom, W. M., van der Pol, W. L., van den Berg, L. H., Wokke, J. H. J., Iannaccone, S. T., & Vrancken, A. F. J. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006282.pub4 · Cited by 109
Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy
Fourcade, S., Ruíz, M., Guilera, C., Hahnen, E., Brichta, L., Naudí, A., Portero‐Otín, M., Dacremont, G., Cartier, N., Wanders, R. J. A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq082 · Cited by 109
Self-citationEmerging roles of histone modifications and HDACs in RNA splicing
Rahhal, R., & Seto, E. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz292 · Cited by 102
Differential Histone Deacetylase mRNA Expression Patterns in Amyotrophic Lateral Sclerosis
Janssen, C., Schmalbach, S., Boeselt, S., Sarlette, A., Dengler, R., & Petri, S. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181ddd404 · Cited by 100
The methylation hypothesis of pharmacoresistance in epilepsy
Kobow, K., El‐Osta, A., & Blümcke, I. (2013) · Epilepsia · doi:10.1111/epi.12183 · Cited by 103
Spinal Muscular Atrophy: From Gene Discovery to Clinical Trials
Nurputra, D. K., Lai, P. S., Harahap, N. I. F., Morikawa, S., Yamamoto, T., Nishimura, N., Kubo, Y., Takeuchi, A., Saito, T., Takeshima, Y., et al. (2013) · Annals of Human Genetics · doi:10.1111/ahg.12031 · Cited by 100
Splicing therapy for neuromuscular disease
Douglas, A. G. L., & Wood, M. J. A. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.04.005 · Cited by 111
Therapeutics development for spinal muscular atrophy
Sumner, C. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.01.010 · Cited by 106
Wirth, B., Garbes, L., & Rießland, M. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.03.003 · Cited by 114
Is spinal muscular atrophy the result of defects in motor neuron processes?
Briese, M., Esmaeili, B., & Sattelle, D. B. (2005) · BioEssays · doi:10.1002/bies.20283 · Cited by 95
Mattis, V. B., Ebert, A. D., Fosso, M. Y., Chang, C. T., & Lorson, C. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp333 · Cited by 103
Molecular Mechanisms of Spinal Muscular Atrophy
Sumner, C. J. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305787 · Cited by 94
Thurmond, J., Butchbach, M. E. R., Palomo, M., Pease, B., Rao, M., Bedell, L. J., Keyvan, M., Pai, G., Mishra, R. K., Haraldsson, M. H., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm061475p · Cited by 93
Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs
Madocsai, C., Lim, S. R., Geib, T., Lam, B. J., & Hertel, K. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.022 · Cited by 92
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells
Angelozzi, C., Borgo, F., Tiziano, F. D., Martella, A., Neri, G., & Brahe, C. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.051177 · Cited by 91
Current and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy
Berger, J., Pujol, A., Aubourg, P. R., & Forss‐Petter, S. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00393.x · Cited by 102
Qiu, X., Xiao, X., Li, N., & Li, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.002 · Cited by 96
Nelson, L. L., Owens, H., Hynan, L. S., Iannaccone, S. T., & AmSMART Group (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.03.005 · Cited by 87
Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy
Hastings, M. L., Berniac, J., Liu, Y. H., Abato, P., Jodelka, F. M., Barthel, L., Kumar, S., Dudley, C., Nelson, M. L., Larson, K. C., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000208 · Cited by 97
Bertini, E., Burghes, A. H. M., Bushby, K. M. D., Estournet, B., Finkel, R. S., Hughes, R. A., Iannaccone, S. T., Melki, J., Mercuri, E. M., Muntoni, F., et al. (2005) · Neuromuscular Disorders · doi:10.1016/j.nmd.2005.07.005 · Cited by 90
Thangapandian, S., John, S., Sakkiah, S., & Lee, K. W. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.06.024 · Cited by 87
SMN mRNA and protein levels in peripheral blood: Biomarkers for SMA clinical trials
Sumner, C. J., Kolb, S. J., Harmison, G. G., Jeffries, N. O., Schadt, K. A., Finkel, R. S., Dreyfuss, G., & Fischbeck, K. H. (2006) · Neurology · doi:10.1212/01.wnl.0000201929.56928.13 · Cited by 97
Novoyatleva, T., Heinrich, B., Tang, Y., Benderska, N., Butchbach, M. E. R., Lorson, C. L., Lorson, M. A., Ben-Dov, C., Fehlbaum, P., Bracco, L. P., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm284 · Cited by 86
Rudnik‐Schöneborn, S., Berg, C., Zerres, K., Betzler, C., Grimm, T., Eggermann, T., Eggermann, K., Wirth, R., Wirth, B., & Heller, R. (2009) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01200.x · Cited by 81
Mercuri, E. M., Messina, S., Battini, R., Berardinelli, A. L., Boffi, P., Bono, R., Bruno, C., Carboni, N., Cini, C., Colitto, F., et al. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2005.11.010 · Cited by 80
Kissel, J. T., Elsheikh, B., King, W. M., Freimer, M. L., Scott, C., Kolb, S. J., Reyna, S. P., Crawford, T. O., Simard, L. R., Krosschell, K. J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23904 · Cited by 84
The splicing machinery is a genetic modifier of disease severity
Nissim‐Rafinia, M., & Kerem, B. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.07.005 · Cited by 81
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Mai, A., Rotili, D., Valente, S., & Kazantsev, A. G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649349 · Cited by 80
Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585
Schreml, J., Rießland, M., Paterno, M., Garbes, L., Roßbach, K., Ackermann, B., Kramer, J. S., Somers, E., Parson, S. H., Heller, R., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.222 · Cited by 78
Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy
Ahmad, S., Bhatia, K., Kannan, A., & Gangwani, L. (2016) · Journal of Experimental Neuroscience · doi:10.4137/jen.s33122 · Cited by 91
Biondi, O., Grondard, C., Lécolle, S., Deforges, S., Pariset, C. C., Lopes, P., Cifuentes-Díaz, C., Li, H., Gaspera, B. D., Chanoine, C., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3237-07.2008 · Cited by 91
Small Molecules in Development for the Treatment of Spinal Muscular Atrophy
Calder, A. N., Androphy, E. J., & Hodgetts, K. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00670 · Cited by 81
Stimulating Full-Length SMN2 Expression by Delivering Bifunctional RNAs via a Viral Vector
Baughan, T. D., Shababi, M., Coady, T. H., Dickson, A., Tullis, G. E., & Lorson, C. L. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.012 · Cited by 75
A microarray configuration to quantify expression levels and relative abundance of splice variants
Fehlbaum, P. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni047 · Cited by 74
Metadata
- Authors
- Brichta, L.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Brichta, L.
- ORCID
- Brichta, L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-05
- Volume
- 12
- Issue
- 19
- Pages
- 2481-2489
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2151318390
- Cited by
- 382
- References
- 41
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 12 · 2018: 8 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 15 · 2013: 31 · 2012: 18
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- valproic acid, spinal muscular atrophy, SMN2, SMN1, SR proteins, alternative splicing, exonic splicing enhancers, drug repurposing, inherited neuromuscular disease
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Dose-Response Relationship, Drug, Exons, Fibroblasts, Gene Expression Regulation, Hippocampus, Humans, Muscular Atrophy, Spinal, Nerve Tissue Proteins, Organ Culture Techniques, RNA Splicing, RNA, Messenger, Time Factors, Transcription, Genetic, Valproic Acid, Blotting, Western, Genetic Therapy, Rats, Wistar, Gene Deletion, GABA Agents, Reverse Transcriptase Polymerase Chain Reaction, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.